Abstract
Abstract Background and Aims Depression is highly prevalent and related to increased morbidity and mortality in patients on dialysis, but less is known among patients with earlier stages of CKD. This study investigated the associations between depression and clinical outcomes in patients with CKD not receiving dialysis. Method We identified 157 398 adults with CKD stages 3–5 not previously diagnosed with depression from the Stockholm CREAtinine Measurements (SCREAM) project. The primary outcomes included hospitalization, CKD progression (>40% decline in eGFR, initiation of kidney replacement therapy, or death due to CKD), major adverse cardiovascular events (MACE; myocardial infarction, stroke, or cardiovascular death), and all-cause mortality. Survival analyses were used to estimate the associations between incident depression and adverse health outcomes, adjusting for socio-demographics, kidney disease severity, healthcare utilization, comorbidities, and concurrent use of medications. Results During a median follow-up of 5.1 (interquartile range: 2.3–8.5) years, 12 712 (8.1%) patients received an incident diagnosis of depression. A total of 634 471 hospitalizations (4,600 935 hospitalized days), 42 866 MACEs, and 66,635 deaths were recorded, and 9 795 individuals met the criteria for CKD progression. In the multivariable-adjusted analyses, incident depression was associated with an elevated rate of hospitalized days (rate ratio: 1.77, 95% confidence interval [CI]: 1.71–1.83), as well as an increased rate of CKD progression (hazard ratio [HR]: 1.38, 95% CI: 1.28–1.48), MACE (HR: 1.22, 95% CI: 1.18–1.27), and all-cause mortality (HR: 1.41 95% CI: 1.37–1.45). The association with CKD progression was more evident after one year of depression diagnosis (HR: 1.47, 95% CI: 1.36–1.59). Results were consistent across a range of sensitivity analyses. Conclusion Among patients with non-dialysis-dependent CKD stages 3–5, incident depression is associated with poor prognosis, including hospitalization, CKD progression, MACE, and all-cause mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
